Cargando…
Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice
Apart from cardiotoxicity, the chemotherapeutic agent doxorubicin (DOX) provokes acute and long-term vascular toxicity. Dexrazoxane (DEXRA) is an effective drug for treatment of DOX-induced cardiotoxicity, yet it remains currently unknown whether DEXRA prevents vascular toxicity associated with DOX....
Autores principales: | Bosman, Matthias, Krüger, Dustin N., Favere, Kasper, De Meyer, Guido R. Y., Franssen, Constantijn, Van Craenenbroeck, Emeline M., Guns, Pieter-Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684076/ https://www.ncbi.nlm.nih.gov/pubmed/38015959 http://dx.doi.org/10.1371/journal.pone.0294848 |
Ejemplares similares
-
Doxorubicin-induced cardiovascular toxicity: a longitudinal evaluation of functional and molecular markers
por: Bosman, Matthias, et al.
Publicado: (2023) -
Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity
por: Bosman, Matthias, et al.
Publicado: (2021) -
Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma
por: Narayan, Hari K, et al.
Publicado: (2019) -
Cisplatin/dexrazoxane/doxorubicin: Neutropenia and thrombocytopenia: case report
Publicado: (2020) -
Effect of Dexrazoxane and Amifostine on the Vertebral Bone Quality of Doxorubicin Treated Male Rats
por: Mwale, F, et al.
Publicado: (2008)